BNGO
$1.13
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Recent News
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?
Here is how Black Diamond (BDTX) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
Bionano Genomics Inc (BNGO) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Cost ...
Bionano Genomics Inc (BNGO) reports a 21% revenue increase and significant cost reductions, setting a strong financial outlook for the remainder of 2025.
Bionano (BNGO) Q3 2025 Earnings Call Transcript
Erik Holmlin: Thank you, Kelly, and good afternoon, everyone. At Bionano Genomics, Inc., our focus is on transforming pathology, which is the medical discipline that investigates disease, including its causes, developments, and effects. Over the last year, we have taken decisive steps to transform our business model away from one based in aggressively growing the installed base toward a model that's driving utilization of our solutions within a subset of our existing OGM and VIA software user base.
iBio, Inc. (IBIO) Reports Q1 Loss
iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of +83.78% and +86.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?